Product Description
Mechanisms of Action: TXA2 Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: India
Approved Indications: None
Known Adverse Events: None
Company: Cairo University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Autism Spectrum Disorder
Phase 1: Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PEALUT - STROKE | N/A |
Not yet recruiting |
Ischemic Stroke |
2026-12-01 |
|
| HP-00099288 | N/A |
Recruiting |
Affective Disorders, Psychotic|Psychotic Disorders|Schizophrenia |
2025-03-01 |
|
| LuMus2-2023 | N/A |
Completed |
Healthy Volunteers |
2024-05-02 |
|
| PL-PC19 | N/A |
Completed |
Cognitive Dysfunction|COVID-19|Cognition Disorders |
2022-02-15 |